AKT1 and breast cancer: In addition, targeted therapies beyond HER2, including inhibitors of PI3K/AKT/mTOR pathway, cyclin-dependent kinases (CDKs) and poly (ADP-ribose) polymerase (PARP), have been applied in clinical practice to prolong the survival for patients diagnosed with BC (Figure 1).